Company research
Nurix Therapeutics, Inc.
CIK 1549595Updated Nov 17, 2026
NRIX price & chart
Loading TradingView…
NASDAQ:NRIX on TradingView ↗About the company
Nurix Therapeutics is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, the next frontier in innovative drug design aimed at improving treatment options for patients with cancer and autoimmune diseases. Nurix’s wholly owned, clinical stage pipeline includes degraders of Bruton’s tyrosine kinase (BTK), a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene B (CBL-B), an E3 ligase that regulates activation of multiple immune cell types including T cells and NK cells. Nurix also is advancing multiple potentially first-in-class or best-in-class degraders and degrader antibody conjugates (DACs) in its preclinical pipeline. Nurix’s partnered drug discovery pipeline consists of a preclinical stage degrader of STAT6, SAR448272/NX-3911, in collaboration with Sanofi, a clinical stage degrader of IRAK4, GS6791, in collaboration with Gilead, as well as multiple additional programs under collaboration agreements with Gilead Sciences, Inc., Sanofi S.A. and Pfizer Inc., within which Nurix retains certain options for co-development, co-commercialization and profit sharin…
In the news
Roche announces global collaboration with Nurix Therapeutics to co-develop and co-commercialise potential best-in-class BTK degrader bexobrutideg across malignant haematology, immunology and neurology ↗
Nurix Therapeutics to Participate in Upcoming Investor Conferences ↗
Recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2026 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 1,195,298,000Source | 522,472,000Source | 513,600,000Source | 535,540,000Source | 591,555,000Source | 511,031,000Source | 636,130,000Source | 615,043,000Source | 688,135,000Source | 669,343,000Source | 355,598,000Source | 416,759,000Source |
| Property, Plant and Equipment, NetUSD | 19,407,000Source | 20,498,000Source | 17,069,000Source | 20,007,000Source | 18,773,000Source | 18,557,000Source | 21,697,000Source | 18,449,000Source | 22,490,000Source | 17,757,000Source | 16,808,000Source | 17,163,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 720,242,000Source | 78,438,000Source | 99,044,000Source | 67,685,000Source | 84,260,000Source | 116,790,000Source | 71,195,000Source | 75,916,000Source | 246,960,000Source | 109,997,000Source | 54,627,000Source | 64,474,000Source |
| Assets, CurrentUSD | 1,103,692,000Source | 440,603,000Source | 456,043,000Source | 456,481,000Source | 515,330,000Source | 450,217,000Source | 554,394,000Source | 563,703,000Source | 606,819,000Source | 619,387,000Source | 295,503,000Source | 318,449,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 35,437,000Source | 11,774,000Source | 7,991,000Source | 12,952,000Source | 10,549,000Source | 7,078,000Source | 13,662,000Source | 14,023,000Source | 13,878,000Source | 9,804,000Source | 7,595,000Source | 9,308,000Source |
| Operating Lease, Right-of-Use AssetUSD | 48,631,000Source | 53,028,000Source | 27,083,000Source | 50,107,000Source | 50,214,000Source | 28,835,000Source | 51,657,000Source | 26,361,000Source | 50,517,000Source | 28,139,000Source | 31,142,000Source | 12,345,000Source |
| Other Assets, NoncurrentUSD | 7,954,000Source | 7,375,000Source | 3,032,000Source | 7,977,000Source | 6,337,000Source | 3,141,000Source | 7,414,000Source | 5,629,000Source | 7,341,000Source | 3,159,000Source | 3,823,000Source | 4,022,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 226,987,000Source | 150,220,000Source | 136,744,000Source | 132,913,000Source | 143,952,000Source | 140,338,000Source | 155,237,000Source | 134,126,000Source | 149,388,000Source | 142,350,000Source | 155,105,000Source | 113,063,000Source |
| Stockholders’ equity: | ||||||||||||
| Preferred Stock, Value, IssuedUSD | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source |
| Common Stock, Value, IssuedUSD | 109,000Source | 77,000Source | 67,000Source | 104,000Source | 76,000Source | 64,000Source | 103,000Source | 76,000Source | 102,000Source | 76,000Source | 49,000Source | 47,000Source |
| Retained Earnings (Accumulated Deficit)USD | -630,128,000Source | -925,005,000Source | -680,220,000Source | -1,179,935,000Source | -838,584,000Source | -631,264,000Source | -1,090,400,000Source | -795,120,000Source | -1,003,226,000Source | -738,769,000Source | -545,200,000Source | -401,252,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | -210,000Source | 119,000Source | 344,000Source | -145,000Source | -20,000Source | -135,000Source | 56,000Source | 226,000Source | 105,000Source | 150,000Source | -655,000Source | -4,319,000Source |
| Stockholders' Equity Attributable to ParentUSD | 968,311,000Source | 372,252,000Source | 376,856,000Source | 402,627,000Source | 447,603,000Source | 370,693,000Source | 480,893,000Source | 480,917,000Source | 538,747,000Source | 526,993,000Source | 200,493,000Source | 303,696,000Source |
| Additional Paid in Capital, Common StockUSD | 1,598,540,000Source | 1,297,061,000Source | 1,056,665,000Source | 1,582,603,000Source | 1,286,131,000Source | 1,002,028,000Source | 1,571,134,000Source | 1,275,735,000Source | 1,541,766,000Source | 1,265,536,000Source | 746,299,000Source | 709,220,000Source |
| Liabilities and EquityUSD | 1,195,298,000Source | 522,472,000Source | 513,600,000Source | 535,540,000Source | 591,555,000Source | 511,031,000Source | 636,130,000Source | 615,043,000Source | 688,135,000Source | 669,343,000Source | 355,598,000Source | 416,759,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 130,742,000Source | 82,350,000Source | 86,296,000Source | 72,020,000Source | 75,614,000Source | 80,779,000Source | 92,199,000Source | 89,988,000Source | 86,471,000Source | 95,854,000Source | 86,958,000Source | 70,655,000Source |
| Operating Lease, Liability, CurrentUSD | 3,241,000Source | 3,791,000Source | 6,553,000Source | 3,221,000Source | 5,235,000Source | 7,934,000Source | 3,202,000Source | 6,639,000Source | 2,824,000Source | 8,014,000Source | 7,489,000Source | 5,530,000Source |
| Accounts Payable, CurrentUSD | 32,984,000Source | 8,609,000Source | 3,918,000Source | 12,208,000Source | 5,954,000Source | 2,813,000Source | 10,293,000Source | 8,397,000Source | 11,215,000Source | 11,482,000Source | 6,401,000Source | 5,064,000Source |
| Operating Lease, Liability, NoncurrentUSD | 62,091,000Source | 52,695,000Source | 20,590,000Source | 54,922,000Source | 46,696,000Source | 20,885,000Source | 55,453,000Source | 19,984,000Source | 52,906,000Source | 20,289,000Source | 23,125,000Source | 6,434,000Source |
| Additional Financial Items | ||||||||||||
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 1,100,000,000Source | 428,800,000Source | 448,100,000Source | 443,500,000Source | 485,800,000Source | 443,100,000Source | 540,700,000Source | 549,700,000Source | 592,900,000Source | 609,600,000Source | 287,900,000Source | 309,100,000Source |
| Short-term InvestmentsUSD | — | — | — | — | — | — | — | — | — | — | — | 244,667,000Source |
| Accounts Receivable, after Allowance for Credit Loss, Current | —Source | — | — | — | —Source | — | — | — | — | — | — | — |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2026 | Q3 2025 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation and amortization | — | — | — | — | — | — | —Source | —Source | —Source | —Source | —Source | —Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 9,404,000Source | 8,722,000Source | 37,965,000Source | 33,929,000Source | 33,673,000Source | 28,131,000Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts ReceivableUSD | — | — | — | — | — | — | — | — | — | 0Source | 0Source | -6,000,000Source |
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | — | -461,000Source | -3,209,000Source | -630,000Source | 5,209,000Source | 1,614,000Source | 85,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -71,914,000Source | -61,087,000Source | -249,465,000Source | -172,584,000Source | -81,365,000Source | -159,807,000Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | -123,826,000Source | 25,533,000Source | 147,853,000Source | -257,713,000Source | 68,301,000Source | 27,198,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | 1,045,000Source | 3,485,000Source | 14,002,000Source | 9,273,000Source | 8,401,000Source | 12,244,000Source |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 19,975,000Source | 1,473,000Source | 238,642,000Source | 485,667,000Source | 3,217,000Source | 117,192,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | -175,765,000Source | -34,081,000Source | 137,030,000Source | 55,370,000Source | -9,847,000Source | -15,417,000Source |
| Additional Financial Items | ||||||||||||
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | — | — | 1,100,000,000Source | 428,800,000Source | 443,500,000Source | 485,800,000Source | 540,700,000Source | 549,700,000Source | 592,900,000Source | 609,600,000Source | 287,900,000Source | 309,100,000Source |
| Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber PropertyUSD | — | — | — | — | — | — | -160,000Source | 0Source | -89,000Source | -31,000Source | -556,000Source | -9,000Source |
| General and Administrative ExpenseUSD | — | — | 34,353,000Source | 13,159,000Source | 15,594,000Source | 14,282,000Source | 14,610,000Source | 11,654,000Source | 52,743,000Source | 45,944,000Source | 42,902,000Source | 37,997,000Source |
| Income Tax Expense (Benefit)USD | — | — | 13,606,000Source | 0Source | -271,000Source | 760,000Source | 0Source | 0Source | 760,000Source | 270,000Source | — | 0Source |
| Marketable Securities, Realized Gain (Loss), Excluding Other-than-temporary Impairment LossUSD | — | — | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | — | — | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | 549,807,000Source | -86,421,000Source | -89,535,000Source | -43,464,000Source | -87,174,000Source | -56,351,000Source | -264,457,000Source | -193,569,000Source | -143,948,000Source | -180,360,000Source |
| Operating ExpensesUSD | — | — | 113,613,000Source | 99,279,000Source | 103,247,000Source | 92,378,000Source | 98,747,000Source | 81,317,000Source | 369,646,000Source | 267,576,000Source | 232,050,000Source | 222,494,000Source |
| Operating Lease, ExpenseUSD | — | — | 2,600,000Source | 3,900,000Source | 2,600,000Source | 3,700,000Source | 2,600,000Source | 2,200,000Source | 13,300,000Source | 9,000,000Source | 6,800,000Source | 5,900,000Source |
| Payments to Acquire InvestmentsUSD | — | — | — | — | — | — | — | — | — | — | — | 239,366,000Source |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | 18,004,000Source | 0Source | 0Source | 289,763,000Source | 0Source | 19,400,000Source |
| Proceeds from Stock Options ExercisedUSD | — | — | — | — | — | — | 375,000Source | 221,000Source | — | — | — | 1,078,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | — | — | —Source | —Source | —Source | —Source | —Source | —Source | — | — | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2026 | Q3 2025 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | 673,064,000Source | 7,894,000Source | 9,043,000Source | 44,056,000Source | 6,252,000Source | 18,453,000Source | 83,980,000Source | 54,549,000Source | 76,987,000Source | 38,627,000Source |
| Operating Income (Loss)USD | — | — | 559,451,000Source | -91,385,000Source | -94,204,000Source | -48,322,000Source | -92,495,000Source | -62,864,000Source | -285,666,000Source | -213,027,000Source | -155,063,000Source | -183,867,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | 563,413,000Source | -86,421,000Source | -89,806,000Source | -42,704,000Source | — | -56,351,000Source | -263,697,000Source | -193,299,000Source | -143,948,000Source | -180,360,000Source |
| Income Tax Expense (Benefit)USD | — | — | 13,606,000Source | 0Source | -271,000Source | 760,000Source | 0Source | 0Source | 760,000Source | 270,000Source | — | 0Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | 549,807,000Source | -86,421,000Source | -89,535,000Source | -43,464,000Source | -87,174,000Source | -56,351,000Source | -264,457,000Source | -193,569,000Source | -143,948,000Source | -180,360,000Source |
| Earnings Per Share, BasicUSD per share | — | — | 4.93Source | -1.03Source | -0.81Source | -0.52Source | -0.79Source | -0.67Source | -3.05Source | -2.88Source | -2.65Source | -3.71Source |
| Earnings Per Share, DilutedUSD per share | — | — | 4.73Source | -1.03Source | -0.81Source | -0.52Source | -0.79Source | -0.67Source | -3.05Source | -2.88Source | -2.65Source | -3.71Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 111,563,067Source | 84,159,336Source | 111,084,423Source | 83,882,477Source | 110,071,668Source | 83,560,795Source | 86,666,907Source | 67,120,266Source | 54,337,901Source | 48,607,990Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 116,152,771Source | 84,159,336Source | 111,084,423Source | 83,882,477Source | 110,071,668Source | 83,560,795Source | 86,666,907Source | 67,120,266Source | 54,337,901Source | 48,607,990Source |
| Additional Financial Items | ||||||||||||
| Common Stock, Dividends, Per Share, DeclaredUSD per share | — | — | — | — | — | — | 0Source | 0Source | 0Source | 0Source | — | — |
| Current Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | — | — | 0Source | 0Source |
| Depreciation, Depletion and Amortization, NonproductionUSD | — | — | — | — | — | — | 2,196,000Source | 2,350,000Source | 8,740,000Source | 9,318,000Source | 7,533,000Source | 5,349,000Source |
| General and Administrative ExpenseUSD | — | — | 34,353,000Source | 13,159,000Source | 15,594,000Source | 14,282,000Source | 14,610,000Source | 11,654,000Source | 52,743,000Source | 45,944,000Source | 42,902,000Source | 37,997,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | — | — | — | — | — | — | — | — | -263,697,000Source | -193,299,000Source | -143,948,000Source | -180,360,000Source |
| Interest and Other IncomeUSD | — | — | 3,962,000Source | 4,964,000Source | 4,398,000Source | 5,618,000Source | 5,321,000Source | 6,513,000Source | 21,969,000Source | 19,728,000Source | 11,115,000Source | 3,507,000Source |
| Marketable Securities, Realized Gain (Loss), Excluding Other-than-temporary Impairment LossUSD | — | — | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | — | — | — |
| Operating ExpensesUSD | — | — | 113,613,000Source | 99,279,000Source | 103,247,000Source | 92,378,000Source | 98,747,000Source | 81,317,000Source | 369,646,000Source | 267,576,000Source | 232,050,000Source | 222,494,000Source |
| Operating Lease, ExpenseUSD | — | — | 2,600,000Source | 3,900,000Source | 2,600,000Source | 3,700,000Source | 2,600,000Source | 2,200,000Source | 13,300,000Source | 9,000,000Source | 6,800,000Source | 5,900,000Source |
| Research and Development ExpenseUSD | — | — | 79,260,000Source | 86,120,000Source | 87,653,000Source | 78,096,000Source | 84,137,000Source | 69,663,000Source | 316,903,000Source | 221,632,000Source | 189,148,000Source | 184,497,000Source |
Filing attachments
ex991_nurixpressrelease202.htm · 8-K · 2026-06-11
EX-99.1 2 ex991_nurixpressrelease202.htm EX-99.1 Document Exhibit 99.1 [Nurix Logo] Nurix Therapeutics to Report Updated Phase 1a/b Results for BTK Degrader Bexobrutideg, Highlighting Durable Responses in Relapsed/Refractory CLL/SLL and Promising Activity in Earlier Lines of Therapy High objective response rate of 92.9% in second line patients who have progressed on a BTK inhibitor and have not received BCL2 inhibitor treatment Updated Phase 1a data further supports a median progression…
Read attachment ↗ex991_nurixpressrelease202.htm · 8-K · 2026-06-08
EX-99.1 2 ex991_nurixpressrelease202.htm EX-99.1 Document Exhibit 99.1 [NURIX LOGO] Nurix Therapeutics Announces Global Collaboration with Roche to Co-Develop and Co-Commercialize Potential Best-in-Class BTK Degrader Bexobrutideg Across Malignant Hematology, Immunology and Neurology Strategic collaboration combines Nurix’s leadership in targeted protein degradation with Roche’s portfolio of B-cell targeted therapies and global clinical and commercialization footprint Robust clinical dev…
Read attachment ↗ex992_nurixpresentation2.htm · 8-K · 2026-06-08
EX-99.2 3 ex992_nurixpresentation2.htm EX-99.2 ex992_nurixpresentation2 Unlocking the Full Potential of Bexobrutideg A Global Collaboration Between Nurix and Roche June 8, 2026 Exhibit 99.2 Forward Looking Statements 2 This presentation contains statements that relate to future events and expectations and as such constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. When or if used in this presentation, the words “anticipate,” “be…
Read attachment ↗ex992_260112xjpmpressrelea.htm · 8-K · 2026-01-12
EX-99.2 3 ex992_260112xjpmpressrelea.htm EX-99.2 Document [Nurix Logo] Exhibit 99.2 Nurix Therapeutics Outlines 2026 Goals and Objectives for Advancing Bexobrutideg and Its Pipeline of Novel Degrader-Based Medicines in Cancer and Autoimmune Diseases Execute a pivotal program for potential best-in-class BTK degrader, bexobrutideg, including Phase 2 and confirmatory Phase 3 studies to support global registration in relapsed/refractory chronic lymphocytic leukemia (r/r CLL) Expand bexobrut…
Read attachment ↗ex991_251206xashxcllxdatap.htm · 8-K · 2025-12-09
EX-99.1 2 ex991_251206xashxcllxdatap.htm EX-99.1 Document [Nurix Logo] Exhibit 99.1 Nurix Therapeutics Presents New Data Demonstrating Durable, Deepening Responses in Phase 1 Trial of Bexobrutideg (NX-5948) in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition Objective response rate (ORR) of 83% including two complete responses in CLL patients in Phase 1a study with median progression free …
Read attachment ↗ex992_251208bexdegwmclinic.htm · 8-K · 2025-12-09
EX-99.2 3 ex992_251208bexdegwmclinic.htm EX-99.2 Document [Nurix logo] Exhibit 99.2 Nurix Therapeutics Presents New Data from the Phase 1 Trial of Bexobrutideg (NX-5948) in Waldenström Macroglobulinemia at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition Objective response rate (ORR) of 75.0% including three very good partial responses (VGPR) in heavily pre-treated Waldenström macroglobulinemia patients With a median follow up of 8.1 months, median duration of…
Read attachment ↗